Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Senaparib 10 mg vs 20 mg Capsules in Healthy Chinese Subjects
NCT05391048Phase 1Completed
- Sponsor
- IMPACT Therapeutics
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of senaparib in solid tumor (2 arms), sponsored by IMPACT Therapeutics. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Jun 2022; status: completed.
02
Drugs
senaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05391048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05391048.